AC Immune SA, the Healthcare sector company, was revisited by a Wall Street analyst on August 5. Analyst Marc Goodman from Leerink Partners maintained a Buy rating on the stock and has a $9.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Goodman has given his Buy rating due to a combination of factors that highlight AC Immune SA’s promising future prospects. The company has reported steady progress in its pipeline, with expectations for significant data releases in the near term. These include interim results from the Phase 2 VacSYn study for Parkinson’s disease and the Phase 2 ABATE trial for Alzheimer’s disease, both of which are anticipated to provide valuable insights into the efficacy of their vaccine candidates.
Additionally, AC Immune is advancing its early-stage programs, with plans for an IND filing for an obesity treatment and the initiation of studies for other promising assets. The company’s strong financial position, with sufficient cash reserves to fund operations into early 2027, further supports its growth potential. Marc Goodman appreciates the company’s robust platform technologies, diverse pipeline, and strategic partnerships, which collectively underpin the Buy rating and a price target of $9.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.